GlassScriptPhysician profile
Danielle Nance
NPI 1689718264
$86,031.66
in general payments reported to CMS, 2019-2025
23 companies · $5,397 in 2025
The $5,397 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $11K · 2021: $21K · 2022: $12K · 2023: $2,801 · 2024: $15K · 2025: $5,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Honoraria: $4,900 · Food and Beverage: $1,407 · Education: $99.99 · Travel and Lodging: $46.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,789.00 |
| Honoraria | $4,900.00 |
| Food and Beverage | $1,407.03 |
| Education | $99.99 |
| Travel and Lodging | $46.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $24,243.04 | 2019-2024 | Givlaari |
| Hema Biologics, LLC | $13,041.90 | 2021-2025 | Sevenfact, Sevenfact |
| Csl Behring | $11,506.29 | 2020-2024 | Hemgenix |
| Bayer Healthcare Pharmaceuticals INC. | $9,787.05 | 2019-2024 | |
| Genzyme Corporation | $9,661.68 | 2019-2025 | |
| Aptevo Therapeutics INC | $5,712.83 | 2019 | |
| Spark Therapeutics, INC. | $3,953.67 | 2019 | |
| Pfizer INC. | $2,534.74 | 2022-2025 | |
| Medexus Pharma, INC. | $2,500.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $2,025.00 | 2023 | Promacta |
| Incyte Corporation | $179.98 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $127.89 | 2023 | Ultomiris |
| Amgen INC. | $121.85 | 2019 | |
| Kite Pharma, INC. | $121.81 | 2023 | Yescarta |
| Bioverativ Therapeutics INC. | $97.31 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $97.10 | 2023 | Nuwiq |
| Genentech USA, INC. | $95.42 | 2019 | |
| Dova Pharmaceuticals | $94.79 | 2021 | |
| Genentech, INC. | $49.95 | 2021 | |
| Novo Nordisk INC | $37.43 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $25.66 | 2025 | Pyrukynd |
| Abbvie INC. | $16.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Nance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.